根据索引心衰事件分析维立西呱的临床结局与治疗反应:VICTORIA试验启示
VICTORIA试验的事后分析按索引事件(近期心衰住院<3个月、3-6个月或仅门诊静脉利尿)分组,评估5050例射血分数<45%的加重性心衰患者的结局及维立西呱疗效。随访中位10.8个月,近期住院<3个月者主要事件率最高(40.9/100患者年),维立西呱在各亚组均降低主要复合终点风险且无治疗异质性,安全事件少见。
要点
- 近期心衰住院<3个月者主要终点风险最高,且风险随时间推移呈梯度下降。
- 维立西呱在全部索引事件亚组中均一致降低心衰住院或心血管死亡风险。
- 维立西呱治疗后症状性低血压和晕厥发生率低,各亚组与安慰剂无差异。
核心结论
- 在加重性慢性心衰患者中,距离索引心衰住院越近,心血管死亡或心衰住院风险越高,与年龄或临床危险因素无关。
- 维立西呱的获益在加重性心衰的风险谱中无显著差异,且随时间推移有获益更大的趋势。
研究设计与样本
- VICTORIA试验的事后分析,为国际、随机、安慰剂对照试验。
- 共纳入5050例近期(<6个月)加重性心衰且射血分数<45%的患者。
- 按索引事件分为:心衰住院<3个月(n=3378)、心衰住院3-6个月(n=871)、仅门诊静脉利尿剂治疗(n=801)。
- 干预为维立西呱滴定至每日10 mg versus 安慰剂,主要终点为心衰住院或心血管死亡复合终点。
主要发现
- 中位随访10.8个月,主要事件率分别为40.9、29.6和23.4事件/100患者年(对应住院<3个月、3-6个月和门诊加重组)。
- 与门诊加重组相比,住院<3个月组主要结局的多变量校正风险比为1.48(95% CI 1.27-1.73)。
- 维立西呱在总体及各亚组中均降低主要结局风险,无治疗异质性证据;全因死亡和心衰住院结果类似。
- 距心衰住院时间与维立西呱治疗的连续关联显示,住院后时间越长有获益更大的趋势。
- 症状性低血压和晕厥在各亚组均不常见,治疗组与安慰剂组无差异。
关键数值与推荐
- 索引事件分组:心衰住院<3个月(n=3378)、心衰住院3-6个月(n=871)、仅门诊静脉利尿剂治疗(n=801)。
- 主要终点事件率:住院<3个月组40.9事件/100患者年,住院3-6个月组29.6事件/100患者年,门诊加重组23.4事件/100患者年。
- 住院<3个月组 vs 门诊加重组的主要终点校正HR为1.48(95% CI 1.27-1.73)。
- 维立西呱剂量为滴定至每日10 mg。
临床怎么用
- 对近期心衰住院患者,应认识到出院后早期(<3个月)是心血管事件高风险窗口。
- 维立西呱可考虑用于近期加重性心衰且射血分数<45%的患者,各索引事件亚组均可获益。
- 使用维立西呱时需监测症状性低血压和晕厥,但试验中发生率低且与安慰剂无差异。
局限性
- 本分析为VICTORIA试验的事后亚组分析,非预设主要分析。
- 索引事件亚组样本量不均衡,门诊加重组仅801例。
- 随访中位时间10.8个月,长期结局未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The period following heart failure hospitalization (HFH) is a vulnerable time with high rates of death or recurrent HFH. OBJECTIVE: To evaluate clinical characteristics, outcomes, and treatment response to vericiguat according to prespecified index event subgroups and time from index HFH in the Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) trial. DESIGN, SETTING, AND PARTICIPANTS: Analysis of an international, randomized, placebo-controlled trial. All VICTORIA patients had recent (<6 months) worsening HF (ejection fraction <45%). Index event subgroups were less than 3 months after HFH (n = 3378), 3 to 6 months after HFH (n = 871), and those requiring outpatient intravenous diuretic therapy only for worsening HF (without HFH) in the previous 3 months (n = 801). Data were analyzed between May 2, 2020, and May 9, 2020. INTERVENTION: Vericiguat titrated to 10 mg daily vs placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was time to a composite of HFH or cardiovascular death; secondary outcomes were time to HFH, cardiovascular death, a composite of all-cause mortality or HFH, all-cause death, and total HFH. RESULTS: Among 5050 patients in the VICTORIA trial, mean age was 67 years, 24% were women, 64% were White, 22% were Asian, and 5% were Black. Baseline characteristics were balanced between treatment arms within each subgroup. Over a median follow-up of 10.8 months, the primary event rates were 40.9, 29.6, and 23.4 events per 100 patient-years in the HFH at less than 3 months, HFH 3 to 6 months, and outpatient worsening subgroups, respectively. Compared with the outpatient worsening subgroup, the multivariable-adjusted relative risk of the primary outcome was higher in HFH less than 3 months (adjusted hazard ratio, 1.48; 95% CI, 1.27-1.73), with a time-dependent gradient of risk demonstrating that patients closest to their index HFH had the highest risk. Vericiguat was associated with reduced risk of the primary outcome overall and in all subgroups, without evidence of treatment heterogeneity. Similar results were evident for all-cause death and HFH. Addtionally, a continuous association between time from HFH and vericiguat treatment showed a trend toward greater benefit with longer duration since HFH. Safety events (symptomatic hypotension and syncope) were infrequent in all subgroups, with no difference between treatment arms. CONCLUSIONS AND RELEVANCE: Among patients with worsening chronic HF, those in closest proximity to their index HFH had the highest risk of cardiovascular death or HFH, irrespective of age or clinical risk factors. The benefit of vericiguat did not differ significantly across the spectrum of risk in worsening HF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02861534.
引用
- Lam CSP, Giczewska A, Sliwa K, et al. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. JAMA Cardiol. 2021. PMID: 33185650. doi:10.1001/jamacardio.2020.6455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。